Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: M.LUTH who wrote (817)	1/8/1998 11:05:00 AM
From: MCorbley	Read Replies (1) \| Respond to of 1115

To: chirodoc (433 ) From: Michael Corbley Monday, Aug 18 1997 2:31PM EST Reply # of 817 Lidakol vs. Zovirax: In 1995, Lidak reported the results of a study comparing Lidakol to Zovirax (aciclovir) 5% cream in 326 patients. Lidakol demonstrated "statistically comparable therapeutic efficacy to Zovirax 5% cream." (quote from annual report). Zovirax 5% cream is the standard approved treatment for cold sores in Europe, but is not available in the U.S. This study was used to show that Lidakol was as effective as the best treatment available, and by inference that Lidakol is effective--period. Lidak also pointed out that Zovirax 5% cream is not the same as, and not as effective as, Zovirax 5% ointment, which is available in the U.S. for limited use in other herpes infections but not for recurrent oral infections. That was in 1995. European sales of Zovirax were $125 million US dollars in 1994.

To: M.LUTH who wrote (817)	1/8/1998 11:51:00 AM
From: luis a. garcia	Respond to of 1115

In Europe Yamanouchi I think did a comparison vs Zovirax and there all they need to prove is equivalence to its counterpart drug. In the US they need to show safety and efficacy for patients..i.e. phase 2 and phase 3. Phase one is the ticket to phase 2 and I don't remember if that is just like r&d...or animal studies... phase two is human safety and phaseIII is efficacy on humans. There is a lot of discussion because this stock has a lot of detractors... people seem to love to hate it? so it makes for an active thread also there is a lot of interest which is good because we all learn from each other.. luis